Nejromidin: instructions for using the medicine, structure, Contraindications
Active material: Ipidakrin
When ATH: N07AA
CCF: Cholinesterase inhibitor
ICD-10 codes (testimony): F07, G60, G61, G62.1, G63.2, G70.2, M54.1, M79.2
When CSF: 02.11.02.01
Manufacturer: OLINEFARM AS (Latvia)
Nejromidin: dosage form, composition and packaging
Pills white, round, Valium, chamfered.
| 1 tab. | |
| ipidakrin | 20 mg |
Excipients: lactose, potato starch, calcium stearate.
10 PC. – packings Valium planimetric (1) – packs cardboard.
10 PC. – packings Valium planimetric (2) – packs cardboard.
10 PC. – packings Valium planimetric (3) – packs cardboard.
10 PC. – packings Valium planimetric (4) – packs cardboard.
10 PC. – packings Valium planimetric (5) – packs cardboard.
Solution / o and p / to the introduction in the form of a transparent, colorless liquid.
| 1 ml | |
| ipidakrin | 5 mg |
Excipients: hydrochloric acid, water d / and.
1 ml – glass ampoule (10) – packs cardboard.
Solution / o and p / to the introduction in the form of a transparent, colorless liquid.
| 1 ml | |
| ipidakrin | 15 mg |
Excipients: hydrochloric acid, water d / and.
1 ml – glass ampoule (5) – packings Valium planimetric (2) – packs cardboard.
Nejromidin: pharmachologic effect
Reversible cholinesterase inhibitor, directly stimulates impulse conduction at the neuromuscular synapse in the central nervous system as a result of the blockade of potassium channels in the membrane. It enhances the action of acetylcholine on smooth muscle, adrenaline, Serotonin, gistamina and oxytocin.
Nejromidin® improves and stimulates neuromuscular transmission; improves the conductivity in the peripheral nervous system, impaired due to injuries, inflammation, effects of local anesthetics, some antibiotics, potassium chloride; increases contractility of smooth muscle organs under the influence of acetylcholine agonists, adrenalinovыh, serotonin, histamine and oxytocin receptors, except potassium chloride; improves memory.
Nejromidin: pharmacokinetics
Absorption
After oral administration, the drug is rapidly absorbed from the gastrointestinal tract. Cmax plasma levels achieved after 1 no.
After parenteral administration of the drug is rapidly absorbed. Cmax plasma levels achieved after 25-30 minutes after administration.
Distribution
Binding to plasma proteins is 40-55%. Ipidacrine rapidly enters the tissue, at steady state plasma levels detected only 2% active substance.
Metabolism
Ipidacrine metabolized in the liver.
Deduction
Report the news, and extrarenal (through blood). Period of poluraspredeleniya 40 m. Renal excretion occurs, mainly, by tubular secretion and only 1/3 the active substance is released by glomerular filtration. After injecting 34.8% excreted in the urine as unchanged.
Nejromidin: testimony
- diseases of the peripheral nervous system (incl. neuritis, polyneuritis, polyneuropathy, polyradiculopathy, myasthenia, myasthenic syndrome of various etiologies);
- bulbar paralysis and paresis;
- recovery period of organic lesions of the central nervous system, accompanied by movement disorders;
- complex therapy of demyelinating diseases;
- bowel atony.
Nejromidin: dosing regimen
Dose and duration of treatment neuromidin® is determined individually, depending on the severity of the disease.
Peripheral nervous system diseases, myasthenia gravis and myasthenic syndrome
Inside the drug is prescribed for 10-20 mg (0.5-1 tab.) 1-3 times / day. Parenteral drug is used / m or m / k on 5-15 mg 1-2 times / day.
The course of treatment is from 1 to 2 Months. If necessary, treatment can be repeated several times with a break in between courses 1-2 Months.
Preventing myasthenic crisis with severe disorders of neuromuscular conduction
Briefly parenterally administered 1-2 ml (15-30 mg) 1.5% solution neuromidin® Injectable, then continue treatment tablets – the dose can be increased to 20-40 mg (1-2 tab.) 5 time / day.
Treatment and prevention of intestinal atony
Inside the drug is prescribed for 20 mg (1 tab.) 2-3 times / day for 1-2 weeks. If the next dose was not adopted in time, in addition it should not be accepted.
The maximum daily dose – 200 mg.
For parenteral administration, the initial dose is 10-15 mg / day for 1-2 weeks. The dose may be increased to 30 mg / day.
Nejromidin: side effects
Reaction, m due to the stimulation of the nicotinic acetylcholine receptor: <10% – drooling, desudation, heartbeat, nausea, diarrhea, jaundice, bradycardia, epigastric pain, increased secretions of the bronchi, convulsions. Drooling and bradycardia can reduce m-holinoblokatorami (incl. atropyn).
In applying the drug at high doses: <10% – dizziness, headache, vomiting, generalized weakness, drowsiness, allergic skin reactions (itch, rash). In these cases, reduce the dose or momentarily (on 1-2 day) the drug is discontinued.
Nejromidin: Contraindications
- epilepsy;
- vestibular disorders;
- extrapyramidal diseases with hyperkinesis;
- angina;
- vыrazhennaya bradycardia;
- bronchial asthma;
- gastric ulcer or duodenal ulcer in the acute phase;
- bowel or urinary tract obstruction;
- pregnancy;
- lactation (breast-feeding);
- childhood;
- hypersensitivity to the drug.
FROM caution used for stomach ulcers and duodenal ulcers, thyrotoxicosis, diseases of the cardiovascular system, as well as in patients with obstructive diseases of the respiratory system, or a history of acute respiratory diseases.
Nejromidin: Pregnancy and lactation
Do not use this drug during pregnancy and lactation (breast-feeding).
The drug has no teratogenic, embryotoxic action.
Nejromidin: Special instructions
The drug is not mutagenic, carcinogenic and immunotoxic action. No effect on the endocrine system.
The patient must inform the doctor about taking other medicines, occurrence of side effects during treatment neuromidin®.
Use in Pediatrics
Use of the drug is contraindicated in children.
Effects on ability to drive vehicles and management mechanisms
During treatment should refrain from driving, as well as activities potentially hazardous activities, require high concentration and speed of psychomotor reactions.
Nejromidin: overdose
If poisoning neuromidin® should immediately call a doctor.
Symptoms: decreased appetite, bronchospasm, lacrimation, desudation, pupillary constriction, nistagmo, increased peristalsis gastrointestinal, spontaneous defecation and urination, vomiting, jaundice, bradycardia, violation of intracardiac conduction, Arrhythmia, decrease in blood pressure, anxiety, alarm, excitation, a sense of fear, ataxia, convulsions, coma, speech disorders, drowsiness, generalized weakness.
Treatment: gastric lavage, use m-holinoblokatorov (incl. atropyn, tsiklodol, metaцin), simptomaticheskaya therapy.
Nejromidin: drug interaction
Nejromidin® sedative effect in combination with the means, CNS depressants.
The action of the drug and the side effects are enhanced when combined with other cholinesterase inhibitors and nicotinic-m means.
In patients with myasthenia increased risk of cholinergic crisis, while the application neuromidin® with other cholinergic agents.
The risk of bradycardia, If beta-blockers were applied before treatment neuromidin®.
The drug can be used in combination with cerebrolysin.
Ethanol increases the side effects of the drug.
Nejromidin® ingestion (in the form of tablets) It weakens the inhibitory effect on neuromuscular transmission and conduction of excitation of peripheral nerves of local anesthetics, aminoglycosides, potassium chloride.
Nejromidin: terms of dispensing from pharmacies
The drug is released under the prescription.
Nejromidin: terms and conditions of storage
The drug is in the form of tablets should be stored out of reach of children, dry, dark place at a temperature no higher than 25 ° C. Shelf life – 3 year.
The drug is in the form of a solution for i / m, and s / c administration (A list) should be kept out of reach of children, dark place at a temperature no higher than 25 ° C. Shelf life – 2 year.
